Trial Profile
Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Carcinoma; Cervical cancer; Cholangiocarcinoma; Colon cancer; Colorectal cancer; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Rectal cancer; Uterine cancer
- Focus Adverse reactions
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 16 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 16 Dec 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.